Post-acute COVID-19 Sequelae in Denmark

Recruiting Observational Study
Non-communicable Disease COVID-19
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
800 (estimated)
Sponsor
Hvidovre University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase)…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Has a blood sample in the clinical biobank related to the OBS-COVID index admission * Aged above 18 years at time of index-admission Exclusion Criteria: * Patients without a Danish personal identification number * Patients who do not understand or speak Danish
Contacts

Ove Andersen, Professor

+4529333262

ove.andersen@regionh.dk

CONTACT

Mette Bendtz Lindstroem, MPH

+4538623308

mlin0062@regionh.dk

CONTACT